Loading...
XKRX
064550
Market cap255mUSD
Dec 05, Last price  
14,590.00KRW
1D
2.24%
1Q
-0.34%
Jan 2017
97.96%
IPO
14.88%
Name

BioneerCorp

Chart & Performance

D1W1MN
XKRX:064550 chart
P/E
P/S
1.28
EPS
Div Yield, %
Shrs. gr., 5y
3.54%
Rev. gr., 5y
51.95%
Revenues
293.98b
+11.68%
20,533,917,88023,904,100,69017,853,516,18020,833,715,30721,703,614,69923,267,735,47424,077,825,95636,292,396,635206,987,464,643223,743,694,062218,394,453,243263,236,802,635293,975,485,000
Net income
-20.58b
L+94.43%
-8,022,353,080-7,152,484,830-13,559,179,820-5,372,140,420-14,418,909,089-9,941,285,943-8,818,353,336-7,826,653,51057,899,192,63027,159,523,57012,076,878,840-10,587,029,811-20,584,198,000
CFO
-13.48b
L
-2,714,095,840-3,787,214,090-4,314,334,030407,678,862-2,511,535,212-3,902,011,230-8,113,572,202-5,589,453,06295,705,376,69653,174,659,3108,805,263,1774,135,856,100-13,476,386,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.
IPO date
Dec 29, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT